Korean Tagrisso Launch Builds On Extensive Local Data
This article was originally published in PharmAsia News
Executive Summary
AstraZeneca's Tagrisso has debuted in South Korea, raising hopes and treatment options for certain types of lung cancer patients, but the product will face immediate local direct competition from Hanmi’s recently launched rival olmutinib.